Observational analysis shows functional drug response predicts clinical outcomes in acute myeloid leukemia, suggesting enhanced treatment stratification.
Key Points
EVDR scores significantly improve prediction of composite marrow remission in acute myeloid leukemia, highlighting a better treatment response.
In patients with acute myeloid leukemia, EVDR predicts overall survival with a multivariate hazard ratio of 0.78, supporting individualized therapy planning.
Analysis of cryopreserved samples via microscopy confirmed strong correlation between drug susceptibility and clinical outcomes in acute myeloid leukemia.
Integrating EVDR with existing genetic frameworks aids risk assessment, particularly in the complex intermediate-risk group in acute myeloid leukemia.